AIM ImmunoTech Commences Key Study for Pancreatic Cancer Treatment in Partnership with AstraZeneca

OCALA, Fla., Feb. 14, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. AIM is making strides in the medical community with the announcement of its latest development in cancer research. The first participant has received a dose in the Phase 1b/2 clinical trial in the Netherlands, marking a significant milestone for the study which explores the effectiveness of Ampligen® (rintatolimod) in combination with AstraZeneca's Imfinzi (durvalumab) in treating patients with pancreatic cancer. The study aims to assess the safety, tolerability, and preliminary efficacy of the combination therapy.

Exploring New Frontiers in Pancreatic Cancer Treatment

Pancreatic cancer remains one of the most lethal forms of cancer, with a need for more effective treatments. AIM ImmunoTech's Ampligen® has shown promise in previous studies, and when combined with AstraZeneca's Imfinzi, it is touted to enhance the patient's immune response against cancer cells. The collaboration brings together AIM's expertise in immunological treatments with AstraZeneca's established presence in oncology.

Phase 1b/2 Study: A Step Toward Innovative Care

The trial will take place in multiple stages, starting with the Phase 1b portion to determine the optimal dose of the combination treatment. Upon successful completion, the study will progress to Phase 2 where the focus will shift to evaluating the efficacy of the treatment. Researchers are optimistic that this novel approach could lead to a new standard of care for those suffering from pancreatic cancer.

Investor Outlook on AIM ImmunoTech and AstraZeneca

Investors and stakeholders in the pharmaceutical sector are watching closely as the trial progresses. Positive results could have a profound impact on the stocks of both AIM ImmunoTech AIM and AstraZeneca AZN. Furthermore, successful outcomes may position the companies as leaders in cancer immunotherapy, potentially providing a boon to their market positions and to patients in need of more effective treatment options.

ClinicalTrial, Immunotherapy, Cancer